United Kingdom

People: argenx SE (ARGX.BR)

ARGX.BR on Brussels Stock Exchange

4:35pm BST
Change (% chg)

€1.70 (+1.29%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Klein, Pamela 

Dr. Pamela Klein serves as Non-Executive Independent Member of the Board at argenx SE since April 2016. Dr. Klein is a principal and founder of PMK BioResearch, which offers strategic consulting in oncology drug development to corporate boards, management teams and the investment community, a position she has held since 2008. She currently serves as a member of various scientific advisor boards. Previously, Dr. Klein spent seven years at the National Cancer Institute as Research Director of the NCI-Navy Breast Center, after which she joined Genentech and was VP, Development until 2001. She served as Chief Medical Officer for Intellikine which was acquired by Takeda. She was previously Vice President, Development for Genentech. Dr. Klein holds a Bachelor’s degree in biology from California State University and an M. D. from Stritch School of Medicine, Loyola University Chicago and is trained in internal medicine and medical oncology. She is member of Research and Development committee

Basic Compensation

Total Annual Compensation, EUR 42,500
Restricted Stock Award, EUR --
Long-Term Incentive Plans, EUR --
All Other, EUR --
Fiscal Year Total, EUR 42,500

Options Compensation

  Quantity Market Value
Exercisable -- --
Unexercisable -- --
Exercised -- --